Condition
Myelodysplastic Syndrome Acute Myeloid Leukemia
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06372717Phase 1Recruiting
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
NCT05211570Phase 1Recruiting
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04361058Phase 1Withdrawn
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
Showing all 3 trials